Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition

Cell Reports(2022)10.1016/j.celrep.2022.111095Source: DataRank Database

High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition is a research paper published in Cell Reports (2022). On theSindex it has a DataRank of 0. It has been cited 19 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access19 citations

Download PDF

Cite:

Linked data & code

cellosaurus arrayexpress nct rrid

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (11 grants)Impact (FWCI 1.76)OA: goldTopics (63)IDs (PubMed, PMC, OpenAlex)Annotations (4)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (20)

Sheeba Jacob ORCID,Richard Kurupi ORCID,Krista M. Dalton ORCID,Colin M. Coon,Patricia Greninger

Live enrichment

PubMed:35905710 PMC:PMC10353975 OpenAlex:https://openalex.org/W4288097056

National Cancer Institute

Grant: P30 CA016059

National Cancer Institute

Grant: R01CA215610

National Cancer Institute

Grant: R01 CA249219

National Institutes of Health

Grant: 5R01CA215610-04

ABT-199 based therapies to treat neuroblastoma

National Institutes of Health

Grant: 5R01CA249219-03

Neuroblastoma reliance on DNMT1 through amplified MYCN

National Institutes of Health

Grant: 4P30CA016059-35

Massey Cancer Center Support Grant

Alex's Lemonade Stand Foundation for Childhood Cancer

National Institutes of Health

Novartis

Rally Foundation

AbbVie

FWCI

1.76

Citation Percentile

0.9%

Citation Trend

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttp://www.cell.com/article/S221112472200897X/pdf

GOLDhttp://www.cell.com/article/S221112472200897X/pdf

publisherhttp://www.cell.com/article/S221112472200897X/pdf

publisherhttps://api.elsevier.com/content/article/PII:S221112472200897X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S221112472200897X?httpAccept=text/plain

Fields of Study

Neuroblastoma Research and TreatmentsCancer, Hypoxia, and MetabolismNeurofibromatosis and Schwannoma CasesMedicineBiology0301 basic medicine0303 health sciences03 medical and health sciencesAnimalsCell Line, TumorMiceMitogen-Activated Protein Kinase KinasesMitogen-Activated Protein KinasesNeoplasm Recurrence, LocalNeuroblastomaNeurofibromin 1Protein Kinase InhibitorsProtein Tyrosine Phosphatase, Non-Receptor Type 11

MeSH Terms

AnimalsNeoplasm Recurrence, LocalNeuroblastomaMitogen-Activated Protein KinasesMitogen-Activated Protein Kinase KinasesNeurofibromin 1Cell Line, TumorProtein Kinase InhibitorsMiceProtein Tyrosine Phosphatase, Non-Receptor Type 11

Keywords

Neurofibromin 1NeuroblastomaMAPK/ERK pathwayCancer researchLoss functionKinaseGTPaseAllosteric regulationGene knockdownLimitingBiologyEffectorCell biologyCell cultureGeneticsPhenotypeReceptorNeurofibromatosisGeneMek InhibitorHigh-risk NeuroblastomaShp099Cp: CancerNeurofibromin, Nf1Mitogen-Activated Protein Kinase KinasesQH301-705.5Protein Tyrosine Phosphatase, Non-Receptor Type 11ArticleMiceCell Line, TumorAnimalsBiology (General)Mitogen-Activated Protein KinasesNeoplasm Recurrence, LocalProtein Kinase Inhibitors

Sustainable Development Goals

SDG 0: Good health and well-being

High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition

FAIR Checklist

Authors (20)

Funding (11 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)